Valuation: Apellis Pharmaceuticals, Inc.

Market Cap 5.25B 4.71B 4.36B 3.95B 7.37B 500B 7.46B 52.1B 20.75B 262B 19.71B 19.3B 831B P/E 2024
-20x
P/E 2025 146x
Enterprise Value 5.26B 4.72B 4.36B 3.95B 7.38B 501B 7.47B 52.16B 20.78B 262B 19.74B 19.32B 832B EV / Sales 2024
5.15x
EV / Sales 2025 3.17x
Free-Float
88.57%
Yield 2024 *
-
Yield 2025 -

Last Transcript: Apellis Pharmaceuticals, Inc.

1 day-0.07%
6 months+0.20%
Current year+63.34%
Current year 16.83
Extreme 16.83
41.14
1 year 16.83
Extreme 16.83
41.14
3 years 16.1
Extreme 16.1
73.8
5 years 16.1
Extreme 16.1
94.75
10 years 11.45
Extreme 11.45
94.75
Manager TitleAgeSince
Director of Finance/CFO 55 01/10/2017
Chief Tech/Sci/R&D Officer 59 03/01/2023
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap. Importance
14/05/26 Tender

Director

-63,416 0.0496%
14/05/26 Tender

Director

-297,904 0.2330%
14/05/26 Tender

General Counsel

-928,388 0.7263%
Change 5-day change 1-year change 3-year change Capi.($)
-0.07%-.--%+37.78%-13.69% 5.25B
+0.50%+0.36%+55.89%+129.96% 1,143B
+0.86%+4.50%+42.43%+86.15% 647B
-0.14%-1.07%+25.42%+105.85% 506B
-0.05%+2.28%+49.14%+67.74% 384B
-0.63%-4.97%+60.15%+37.06% 350B
+0.34%+2.15%+25.26%+54.27% 293B
-0.45%+1.16%+1.74%+26.08% 265B
+0.87%+2.94%+55.18%+72.74% 242B
+0.08%+1.72%+32.15%+107.78% 197B
Average +0.32%+0.74%+38.51%+67.39% 403.28B
Weighted average by Cap. +0.60%+0.71%+42.62%+88.88%

Financials

2024 2025
Net sales 781M 701M 648M 587M 1.1B 74.42B 1.11B 7.75B 3.09B 38.94B 2.93B 2.87B 124B 1B 901M 833M 754M 1.41B 95.6B 1.43B 9.96B 3.97B 50.03B 3.77B 3.69B 159B
Net income -198M -178M -164M -149M -278M -18.85B -281M -1.96B -782M -9.86B -743M -727M -31.31B 22.39M 20.09M 18.57M 16.82M 31.42M 2.13B 31.8M 222M 88.44M 1.12B 84.01M 82.24M 3.54B
Net Debt 53.65M 48.13M 44.5M 40.3M 75.3M 5.11B 76.21M 532M 212M 2.67B 201M 197M 8.49B 6.57M 5.9M 5.45M 4.94M 9.23M 626M 9.34M 65.2M 25.97M 328M 24.67M 24.15M 1.04B
Projected Income Statement - Annual - Apellis Pharmaceuticals, Inc.
Logo Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of novel therapeutic compounds to treat diseases with high unmet needs through the inhibition of the complement system. SYFOVRE (pegcetacoplan injection) is the Company’s approved treatment for geographic atrophy secondary to age-related macular degeneration (GA). Its EMPAVELI (pegcetacoplan) is for the treatment of paroxysmal nocturnal hemoglobinuria (PNH). Its Aspaveli (pegcetacoplan) for the treatment of adults with PNH who are anemic after treatment with a C5 inhibitor for at least three months. Systemic pegcetacoplan has also been approved for the treatment of PNH in Japan, Saudi Arabia, Australia, the United Kingdom and other jurisdictions. Systemic pegcetacoplan is marketed under the trade name EMPAVELI in the United States, Saudi Arabia and Australia and Aspaveli in the European Union, Japan and the United Kingdom.
Employees
736
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Apellis Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. APLS Stock